

FIRST LIGHT

30 April 2024

Chg (%)

(4bps)

(2bps)

0.0

0.6

04

2.1

(0.8)

Chg

(\$ mn)

442.2

(504.2)

26-Apr

4.66

7.19

83.35

89.5

38,240

17,651

73.730

25-Apr

58.1

3.2

RESEARCH

AXIS BANK | TARGET: Rs 1,252 | +11% | HOLD

Moderate business growth; PAT supported by other income

INDUSIND BANK | TARGET: Rs 1,881 | +26% | BUY

Stable performance

SBI CARD | TARGET: Rs 775 | +3% | HOLD

Trend of lower NIM, higher credit cost persists

ADITYA BIRLA SUN LIFE AMC | TARGET: Rs 520 | -4% | HOLD

Better quarter

SUMMARY

AXIS BANK

- NII growth remained subdued at 11% YoY on higher cost of funds in line with moderate business growth; credit/deposit grew 14%/13% YoY
- NIM rose 5bps QoQ to 4.06%, while other income backed by higher trading gain and muted opex supported PAT growth of 17% YoY
- Asset quality stable though price factored in overall performance; downgrade to HOLD with Rs 1,252 TP, set at 1.7x FY26E ABV

Click here for the full report.

INDUSIND BANK

- Healthy business growth supported by CFD aided 16% YoY rise in Q4 income, while higher opex led to flat PPOP (1% QoQ)
- Reported NIM down 3bps QoQ at 4.3% on higher borrowings cost which offset yield rise; asset quality improved sequentially
- Lower GGM-based TP to Rs 1,881, valuing it at 1.8x FY26E P/ABV, as we tweak growth estimates. Maintain Buy

Click here for the full report.

BOBCAPS Research research@bobcaps.in



Source: Bank of Baroda Economics Research

Daily macro indicators

25-Apr

4.70

7.21

83.33

89.0

38,086

17,285

74,339

24-Apr

(384.1)

507.5

Indicator

US 10Y

yield (%) India 10Y

yield (%) USD/INR

Brent Crude

(US\$/bbl)

Hang Seng

Sensex

India FII

(US\$ mn)

FII-D

FII-E

Dow



SBI CARD

- NIM fell 67bps YoY in Q4 on higher cost of funds; we bake in decline of 10.7%/ 10.9% for FY25E/FY26E vs. 10.7% in FY24
- NIM fell 67bps YoY in Q4 on higher cost of funds; we bake in decline of 10.7%/ 10.9% for FY25E/FY26E vs. 10.7% in FY24
- Maintain HOLD, valuing it at an unchanged 21x FY26E P/E for a revised TP of Rs 775 (from Rs 800)

Click here for the full report.

ADITYA BIRLA SUN LIFE AMC

- QAAUM grew 21% YoY to Rs 3.3tn in Q4 with equity assets rising even faster at 31%; however, market share declined
- SIP book showed strong double-digit growth and beat industry growth QoQ (25% vs 10%) but lagged on a YoY basis (25% vs 35%)
- TP raised to Rs 520 (from Rs 500) on unchanged valuation of 17x FY26E P/E; maintain HOLD

Click here for the full report.



AXIS BANK

Banking

Moderate business growth; PAT supported by other income

- NII growth remained subdued at 11% YoY on higher cost of funds in line with moderate business growth; credit/deposit grew 14%/13% YoY
- NIM rose 5bps QoQ to 4.06%, while other income backed by higher trading gain and muted opex supported PAT growth of 17% YoY
- Asset quality stable though price factored in overall performance; downgrade to HOLD with Rs 1,252 TP, set at 1.7x FY26E ABV

Robust business growth: AXSB's advances growth moderated to 14% YoY (+4% QoQ) during Q4FY24 backed by robust growth in retail (20% YoY), while SME grew 17% YoY. Corporate loans saw a modest 7% uptick YoY. Retail growth was mainly fuelled by rural book (+30%), personal loans (+31%) and SBB (+30%). Deposits increased 13% YoY (+6% QoQ) driven by TDs, while QoQ rise in CASA led to an 85bps jump in CASA ratio to 43% (among the best in the industry). Considering deposit constraints and competitive intensity, we trim our credit/deposit estimates by 6%/5% for FY25/FY26 and project a credit/deposit CAGR of 17% over the same.

NIM up QoQ, opex rises: Reported NIM rose 5bps QoQ to 4.06% backed by the rise in spread and interest reversal. Bank expects stable NIM with suitable product mix at both the asset and liability sides. Other income grew 22% QoQ due to trading gains and better DCM performance. Opex increased 25% YoY on higher staff cost (up 35% YoY) while C/I ratio declined 252bps to 47%. PPOP jumped 15% QoQ.

Asset quality steady: QoQ decline in slippages (1.48% vs. 1.34% in Q3) led to improvement in GNPA/NNPA by 15bps/5bps to 1.43%/0.31% while PCR stood at 78.5%. A 14bps QoQ rise in credit cost was attributable to a higher coverage of 1% on full book basis. The bank didn't utilise Covid-related provisions (Rs 50.1bn) and set it aside for the ECL implication. Cumulative Non NPA provision was Rs 121bn, which is 1.3% of Loan.

Adequately capitalised for growth: CET1 stood at 13.7% (CAR at 16.6%), and AXSB is confident of funding credit growth internally (added 44bps of CET1 in FY24). Further, it maintains its guidance of 300-400bps growth in business above industry in the mid term.

BUY to HOLD: AXSB continues to deliver a healthy performance backed by a sustained focus on growth, healthy portfolio mix, stable asset quality and steady investment in network expansion. We revised our growth estimates on a competitive environment while expecting return performance to stay stable. We continue to value AXSB at 1.7x FY26E ABV using the Gordon Growth Model and maintain our SOTP-based TP at Rs 1,252, with Rs 143/sh as value of subsidiaries. With recent price appreciation, we believe positives are factored in and recommend HOLD from BUY.

29 April 2024

Ajit Agrawal research@bobcaps.in

Key changes

	Target	Rating	
	<►	▼	
Ticker/Price		AXSB IN/Rs 1,130	
Market cap		US\$ 42.5bn	
Free float		92%	
3M ADV		US\$ 137.5mn	
52wk high/low		Rs 1,152/Rs 854	
Promoter/FPI/DII		8%/54%/30%	

Source: NSE | Price as of 26 Apr 2024

Key financials

FY24P	FY25E	FY26E
498,945	558,714	659,404
16.2	12.0	18.0
248,614	259,688	304,879
80.7	84.1	98.8
80.7	87.5	101.7
14.0	13.4	11.4
2.3	2.0	1.7
1.8	1.6	1.7
18.0	15.8	15.9
	498,945 16.2 248,614 80.7 80.7 14.0 2.3 1.8	498,945 558,714 16.2 12.0 248,614 259,688 80.7 84.1 80.7 87.5 14.0 13.4 2.3 2.0 1.8 1.6

Source: Company, Bloomberg, BOBCAPS Research | P - Provisional

Stock performance









INDUSIND BANK

Banking

29 April 2024

Stable performance

- Healthy business growth supported by CFD aided 16% YoY rise in Q4 income, while higher opex led to flat PPOP (1% QoQ)
- Reported NIM down 3bps QoQ at 4.3% on higher borrowings cost which offset yield rise; asset quality improved sequentially
- Lower GGM-based TP to Rs 1,881, valuing it at 1.8x FY26E P/ABV, as we tweak growth estimates. Maintain Buy

Healthy business growth: IIB maintained healthy business growth with credit rising 18% YoY (+5% QoQ), while deposits rose 14% YoY (4% QoQ). Loan book was driven by the CFD book (+23% YoY/+6% QoQ), wherein non-vehicle retail outpaced vehicle book driven by unsecured and MFI loan. CCB growth was muted at 13% YoY, but rose 4% QoQ supported by small corporate (33%/7% YoY/QoQ). Deposit growth further accelerated to 14.4% YoY vs. 13.4% in Q3, driven by term deposits (TD) which led to 61bps decline in CASA ratio (37.9% in Q4).

NIM backed by rise on yield; lower provision aided PAT despite cost rise:

Continued recovery in asset yield (+10bps QoQ) backed stable NIM (4.3%) despite a 13bps QoQ rise in CoF (deposit cost rose 4bp). IIB continues to guide for NIM of 4.2-4.3% in FY25. NII growth was healthy at 15% YoY (1.5% QoQ) while non-interest income grew 16% YoY (5% QoQ). Opex stayed elevated on continued investment in human capital and technology that raised C/I ratio by 79bps QoQ to 48.2%. Despite strong topline, PPOP remained flat (9%/1% YoY/QoQ) on higher opex.

Asset quality stable: Slippages fell to Rs 14.2bn (44bps) vs. Rs 17.6bn (56bps) in Q3, where corporate slippages were Rs 1.6bn (vs. Rs 3.1bn) and CFD Rs 12.7bn (vs. Rs 14.5bn). Credit cost (calc.) stood at 113bps vs. 121bps in Q3, which is within the guided range of 110-130bps over FY23-FY26. GNPA/NNPA were stable at 1.9%/0.57% with PCR of 70.6%. Continued decline in the restructured book (to 40bps of advances vs. 48bps in Q3) and SMA book (25bps vs. 19bps) and total provisions of 2.1% (108% of GNPA) provide confidence on asset health. IIB aims to keep 2%/0.5% extra provision on MFI/MHCV book as a buffer given expected volatility.

Maintain BUY: Strong growth momentum in retail, recovery in MFI and a favourable asset-liability mix led to stable margins despite higher costs. We expect IIB to deliver healthy return ratios (ROA/ROE to 2%/17% in FY26 vs. 1.7%/14% in FY23) though growth moderation is expected due to the business environment. We retain BUY and lower our TP to Rs 1,881 (from Rs 1,952) as we tweak estimates (cut EPS by 4%/1% for FY25/FY26) and value TP using the Gordon Growth Model at 1.8x FY26 P/ABV (earlier 1.9x).

Ajit Agrawal

research@bobcaps.in

Key changes

	Target	Rating	
	•	<►	
Ticker/Price		IIB IN/Rs 1,487	
Market cap		US\$ 14.1bn	
Free float		84%	
3M ADV		US\$ 61.4mn	
52wk high/low		Rs 1,695/Rs 1,065	
Promoter/FPI/DII		16%/40%/28%	

Source: NSE | Price as of 29 Apr 2024

Key financials

Y/E 31 Mar	FY24P	FY25E	FY26E
NII (Rs mn)	206,159	236,319	286,062
NII growth (%)	17.2	14.6	21.0
Adj. net profit (Rs mn)	89,770	102,244	131,214
EPS (Rs)	115.5	131.4	168.6
Consensus EPS (Rs)	115.6	135.4	161.0
P/E (x)	12.9	11.3	8.8
P/BV (x)	1.8	1.6	1.4
ROA (%)	1.8	1.8	2.0
ROE (%)	15.2	15.1	16.9

Source: Company, Bloomberg, BOBCAPS Research | P - Provisional

Stock performance







HOLD TP: Rs 775 | A 3%

SBI CARD

NBFC

Trend of lower NIM, higher credit cost persists

- Credit cost soared 50% YoY to Rs 9.4bn (7.9% of loans) in Q4; stress expected to continue in FY25 as well
- NIM fell 67bps YoY in Q4 on higher cost of funds; we bake in decline of 10.7%/ 10.9% for FY25E/FY26E vs. 10.7% in FY24
- Maintain HOLD, valuing it at an unchanged 21x FY26E P/E for a revised TP of Rs 775 (from Rs 800)

High credit cost trend: SBI Card's credit cost soared 50% YoY to Rs 9.4bn in Q4FY24, forming 7.9% of loans (+128bps YoY, +6bps QoQ). The pain is expected to persist in FY25 with management expectations of ~7%. Loan write-offs increased 21% QoQ to Rs 8.6bn. We now bake in credit costs of 7.1%/6.9% for FY25E/FY26E (+9bps/11bps over our previous estimates). Due to decreased corporate spending and the resulting reduced C/I ratio, PAT increased 11% YoY to Rs 6.6bn. GNPA/NNPA rose 41bps/12bps YoY to 2.8%/1%.

Cost of funds remains high: NIM (calc.) slipped 67bps YoY to 10.4% (-56bps QoQ) due to an increase in the cost of funds owing to higher borrowing rates. NIM declined ~105bps YoY to 10.7% at end FY24. NIM of 10.7%/ 10.9% is projected for FY25/FY26 (11.1%/11.4% earlier) and NII to clock 25% CAGR over FY24-FY26 to Rs 83.6bn. Although lower C/I in Q4 (51%) was an aberration and it will bounce back in Q1FY25, we lower our C/I by 155bps/106bps to 57.8%/57.6% for FY25E/FY26E. Baking in Q4 print, we compress FY26E earnings by 3% (+1% for FY25) from earlier estimates to end FY25E/FY26E at Rs 28bn/Rs 35bn.

Corporate spends decline: Although SBI Card maintained its #2 position at end FY24, corporate spends declined 35% YoY (-55% QoQ) to Rs105bn, constituting 13% of the total spends (vs. an avg. of 23% over the last four quarters). B2B spends were completely halted from mid Feb, as vendors gradually transitioned to becoming merchants. It is expected to normalise by Jun/Jul. Total spends grew 26% YoY in FY24 and we expect it to grow 24%/21% YoY in FY25/FY26 to Rs 4tn/ 4.9tn. Cards in force increased 13% YoY to 18.9mn at end Q4. Monthly average UPI spends per account were at Rs 12,500 with more traction in Tier-2+ cities.

Maintain HOLD: We expect the trend of high credit costs to continue though management is taking proactive steps to reduce credit limits. NIMs are expected to be under pressure owing to higher cost of funds. We expect the spends trajectory in FY25/FY26 to be strong. We value the company at an unchanged target P/E of 21x (50% below the long-term trend) at a reduced TP of Rs 775 (previously Rs 800) which carries just 3% upside, leading us to maintain HOLD.

29 April 2024

Mohit Mangal research@bobcaps.in

Key changes

	Target	Rating		
	·			
Ticker/Price		SBICARD IN/Rs 750		
Market cap		US\$ 8.7bn		
Free float		31%		
3M ADV		US\$ 16.3mn		
52wk high/low		Rs 933/Rs 679		
Promoter/FPI/DII		69%/8%/17%		

Source: NSE | Price as of 26 Apr 2024

Key financials

Y/E 31 Mar	FY24P	FY25E	FY26E
NII (Rs mn)	53,319	66,954	83,600
NII growth (%)	18.3	25.6	24.9
Adj. net profit (Rs mn)	24,079	28,020	35,056
EPS (Rs)	25.4	29.5	36.9
Consensus EPS (Rs)	25.4	29.7	37.6
P/E (x)	29.6	25.4	20.3
P/BV (x)	5.9	4.9	4.0
ROA (%)	4.6	4.3	4.4
ROE (%)	22.0	21.1	21.8

Source: Company, Bloomberg, BOBCAPS Research | P - Provisional

Stock performance









ADITYA BIRLA SUN LIFE

| NBFC

29 April 2024

Better quarter

- QAAUM grew 21% YoY to Rs 3.3tn in Q4 with equity assets rising even faster at 31%; however, market share declined
- SIP book showed strong double-digit growth and beat industry growth QoQ (25% vs 10%) but lagged on a YoY basis (25% vs 35%)
- TP raised to Rs 520 (from Rs 500) on unchanged valuation of 17x FY26E P/E; maintain HOLD

Healthy quarter, yet market share loss continues: ABSL AMC's QAAUM grew 21% YoY to Rs 3.3tn at end-Q4FY24 and equity QAAUM increased even faster at 31% YoY to Rs 1.5tn, making up 46% of the total. However, the company's overall QAAUM market share slipped 80bps YoY to 6.9% and equity share fell 70bps to 4.9%. Sequentially, the loss of share has been lower at 10bps for each. Although ABSL AMC's industry ranking has held at #6, management's efforts to protect market share remain a key aspect to watch.

Strong revenue growth: Revenue from operations grew 23% YoY to Rs 3.7bn and other income soared 131% YoY on MTM gains, leading to a 34% rise in total income to Rs 4.4bn. Yield on the equity segment was 68bps, debt was stable at 23-25bps and liquid at 10-13bps. The blended yield (calc.) grew 1bps QoQ to 44bps owing to higher share of equity in the AUM mix. Operating expenses increased 16% YoY and net profit rose 54% to Rs 2.1bn, with core PAT up 35%.

Strong growth in SIP book: ABSL AMC's monthly SIP book advanced 25% YoY to Rs 12.5bn (vs. industry growth of 35%), though on a QoQ basis it beat industry growth (25% vs 10%). It closed Q4 with a total of 3.6mn SIP accounts and AUM of Rs 692bn (+35% YoY). The company registered 0.6mn new SIPs (including STP) for Q4, witnessing 125% YoY growth.

Distribution trends stable: The direct channel accounted for 41% share, MFDs 34% and the banking channel 8% on overall AUM basis. In terms of equity asset distribution, MFDs maintained the lion's share of 53%, followed by national distributors with 20%. The direct channel constituted 18%.

Maintain HOLD: Strong earnings growth lead us to increase our FY25/FY26 estimates by 5%/4%. Strong equity AUM growth along with SIP book is a positive. However, market share losses remain key concerns. Our forecast changes yield a revision in TP to Rs 520 (from Rs 500) based on an unchanged target P/E of 17x on FY26E EPS – a 10% discount to the long-term mean. We maintain HOLD as we await sustainable growth and market share gains before revisiting our estimates.

Mohit Mangal research@bobcaps.in

Key changes

	Target	Rating		
	A	<►		
Ticker/Price		ABSLAMC IN/Rs 539		
Market cap		US\$ 1.9bn		
Free float		7%		
3M ADV		US\$ 1.6mn		
52wk high/low		Rs 569/Rs 331		
Promoter/FPI/DII		87%/2%/5%		

Source: NSE | Price as of 29 Apr 2024

Key financials

Y/E 31 Mar	FY24P	FY25E	FY26E
Core PBT (Rs mn)	7,208	8,491	9,017
Core PBT (YoY)	8.1	17.8	6.2
Adj. net profit (Rs mn)	7,804	8,070	8,833
EPS (Rs)	27.0	27.9	30.6
Consensus EPS (Rs)	27.0	27.9	30.6
MCap/AAAUM (%)	4.7	4.3	4.0
ROAAAUM (bps)	23.5	22.3	22.6
ROE (%)	27.4	24.1	23.7
P/E (x)	20.0	19.3	17.6

Source: Company, Bloomberg, BOBCAPS Research | P - Provisional

Stock performance







NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: BOB Capital Markets Limited Registered office Address: 1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051 SEBI Research Analyst Registration No: INH000000040 valid till 03 February 2025 Brand Name: BOBCAPS Trade Name: www.barodaetrade.com CIN: U65999MH1996G0I098009



Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL – Expected return <-6% Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Companyspecific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.



BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.